Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 32 Show results per page	View Search Criteria \| Help With Results


1.		Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				CRAD001C2239 NCT00363051


2.		Everolimus Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 90				Pharmaceutical / Industry				CRAD001C2240 NCT00410124


3.		Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CRAD001C2325 NCT00412061


4.		RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				Not specified				Other				2003-0948 NCT00081874

Last Modified: 4/30/2007 First Published: 5/28/2004


5.		Phase I/II Study of Everolimus and Gefitinib in Patients With Progressive Glioblastoma Multiforme or Progressive Castrate Metastatic Prostate Cancer (Prostate Cancer Closed to Accrual as of 10/19/2006)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				MSKCC-04010 NCT00085566

Last Modified: 8/29/2006 First Published: 9/25/2004


6.		Phase I/II Study of Everolimus and Imatinib Mesylate in Patients With Chronic Phase Chronic Myelogenous Leukemia That is Not in Complete Cytogenetic Remission After Prior Imatinib Mesylate

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Other, Pharmaceutical / Industry				RPCI-PH-24204 NOVARTIS-CRAD001C2207, NCT00093639

Last Modified: 10/19/2006 First Published: 10/25/2004


7.		Phase I/II Study of Gefitinib and Everolimus in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				MSKCC-04033 NCT00096486

Last Modified: 7/24/2007 First Published: 3/24/2005


8.		Phase I/II Study of AEE788 and Everolimus in Patients With Recurrent or Relapsed Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0409004-01 NOVARTIS-CAEE788A2106, NCT00107237


9.		Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				3 to 21				Other				RAD001 NCT00187174

Last Modified: 5/1/2008 First Published: 3/13/2006


10.		Phase I/II Study of Vatalanib and Everolimus in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI				DUMC-6626-04-12R0 NCT00303732

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute